The best of 2019: an A–Z of neuroscience and neurological disease research

Written by Sharon Salt, Editor

Aducanumab Aducanumab has seen a whirlwind of headlines this year – from the decision to discontinue the global Phase III trials for Alzheimer’s disease (AD) in March, to Biogen (MA, USA) and Eisai (Tokyo, Japan) turning the tables with their announcement in October that they are going to pursue regulatory approval for the drug. With little to no information provided about both circumstances, researchers were left eagerly waiting for any kind of results that would help explain why or what has been happening. Finally, this month, Biogen presented detailed data to help explain why aducanumab had resurfaced from their initial...

To view the full article, please register now for access

It's completely free